Vertex Pharma +4.3% on Exonics acquisition; Crispr rises on deal [Seeking Alpha]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Seeking Alpha
Vertex Pharma +4.3% on Exonics acquisition; Crispr rises on deal - CRISPR Therapeutics AG (NASDAQ:CRSP) | Seeking Alpha Healthcare | On the Move Vertex Pharma +4.3% on Exonics acquisition; Crispr rises on deal Jun. 6, 2019 6:30 PM ET CRISPR Therapeutics AG (CRSP) Jason Aycock Vertex Pharmaceuticals (NASDAQ: VRTX up 4.3% acquiring Exonics Therapeutics Crispr is up 10.9% Vertex will acquire privately held Exonics for an upfront payment of $245M along with potential milestone payments. Meanwhile, Vertex will pay $175M upfront for exclusive worldwide rights to Crispr's "existing and future intellectual property including foundational CRISPR/Cas9 technology, novel endonucleases, single and double cut guide RNAs, and AAV vectors for DMD and DM1 gene editing products." The moves enhance Vertex's capability to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1, the company says. See all stocks on the move » Now read: CymaBay Therapeutics: Targeting Primary
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $102.00 to $95.00. They now have an "outperform" rating on the stock.MarketBeat
- We're Interested To See How CRISPR Therapeutics (NASDAQ:CRSP) Uses Its Cash Hoard To Grow [Yahoo! Finance]Yahoo! Finance
- Capsida Biotherapeutics to Present Preclinical Data for Parkinson's Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $86.00 price target on the stock.MarketBeat
- CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 5/9/24 - Beat
CRSP
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 4/17/24 - Form 4
- CRSP's page on the SEC website